12:03 EDT Catalyst Pharmaceuticals (CPRX) trading halted, volatility trading pause
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharma Patent Trial Against Hetero USA Delayed
- Catalyst Pharmaceutical Partners Signals Confident Growth Path
- Buy Rating on Catalyst Pharma Driven by Strong 2026 Growth Outlook and Favorable Firdapse Litigation Upside
- Catalyst Pharmaceuticals price target raised to $35 from $33 at Citi
- Buy Rating on Catalyst Pharma Backed by Strong Growth, Underpenetrated LEMS Opportunity, and Rising Profitability Post-Royalty Roll-Off